Hepatocellular Carcinoma — Origins and Outcomes
Robin Kate Kelley, Tim F. Greten
Abstract
Pharmacologic inhibition of both the immune-checkpoint molecule PD-L1 and vascular endothelial growth factor improves survival among persons with hepatocellular carcinoma. The success of this combination therapy may depend on the context in which hepatocellular carcinoma arises.
Topics & Concepts
Hepatocellular carcinomaMedicineContext (archaeology)CarcinomaOncologyInternal medicineVascular endothelial growth factorImmune checkpointCancer researchVEGF receptorsCancerImmunotherapyPaleontologyBiologyHepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and BiomarkersCancer Mechanisms and Therapy